Study of TX000045 for lung scarring and high blood pressure in the lungs
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a lung scarring condition confirmed by a CT scan within the last year, showing scarring in at least 10% of your lungs.
- Your lung function (how much air you can blow out) must be between 40% and 80% of normal for your age.
- You need a past heart test (right heart catheterization or echocardiogram) within the last 18 months showing high blood pressure in your lungs.
- You cannot have taken certain blood pressure or lung medicines in the last 30 days (or 180 days for one specific drug).
- If you take medications for your lung scarring, the doses must have been stable for at least 30 days before screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a study database that collects information from adults who have other illnesses that can increase the risk of developing interstitial lung disease (lung scarring). It may help researchers better understand who is at risk and how outcomes change over time.
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests an investigational drug called NS-863 for people with pulmonary hypertension (high blood pressure in the lungs) that is caused by interstitial lung disease (scarring of the lungs). The study will check if the drug is safe and effective in improving your condition.
This study is testing whether a new risk score can better predict outcomes for people who have both chronic lung disease and pulmonary hypertension (high blood pressure in the lungs). If you qualify, the researchers will follow your health over time to see how well the score works.
This trial tests an inhaled medicine that may help people with lung scarring or connective tissue disease who have high blood pressure in the lungs only during exercise. It aims to improve their ability to be active and reduce symptoms.
Hear when a new Hypertension, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.